Alkermes PLC (STU:8AK)
€ 22.2 0 (0%) Market Cap: 3.75 Bil Enterprise Value: 3.41 Bil PE Ratio: 9.49 PB Ratio: 3.24 GF Score: 68/100

Alkermes Plc at Jefferies London Healthcare Conference Transcript

Nov 21, 2019 / 04:00PM GMT
Release Date Price: €16.63 (-1.65%)
Biren N. Amin
Jefferies LLC, Research Division - MD and Senior Equity Research Analyst

Let's get started. My name is Biren Amin. I'm one of the biotech analysts here at Jefferies. I'd like to introduce our next company. We have Alkermes and their CEO, Richard Pops, to give us an overview. And also I think, Richard, you recently announced the acquisition of Rodin Therapeutics, I'm sure you're probably going to discuss that as well.

Richard F. Pops
Alkermes plc - Chairman & CEO

Yes. Good. So then good afternoon, everybody. The presentation is slightly different today than what you might have seen over the past few months. And the title of it is even different, which is this idea that I want to focus your attention on how much is evolving at Alkermes right now. If you haven't been paying attention to Alkermes over the last 4 or 5 months, you probably don't have a very current sense of how dynamic the business is right now and how excited we are about the way the business is evolving.

I will make forward-looking statements, and we always ask you to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot